Dr. Amy B. Heimberger is a nationally acclaimed neurosurgeon-scientist and one of the foremost authorities in neuro-oncology and cancer immunotherapy. She currently serves as Professor and Chief of Neurosurgical Oncology at Northwestern University Feinberg School of Medicine and as Scientific Director of the Malnati Brain Tumor Institute at the Robert H. Lurie Comprehensive Cancer Center, a National Cancer Institute (NCI)-designated Comprehensive Cancer Center.

Dr. Heimberger was appointed by President Joseph R. Biden to the National Cancer Advisory Board, where she plays a pivotal role in shaping the nation's cancer research priorities and strategic direction. In addition to this prestigious appointment, she holds leadership positions in several federal and academic consortia, contributing her expertise to initiatives that advance immunotherapeutic innovation and accelerate clinical translation in oncology.

Renowned for her groundbreaking research, Dr. Heimberger has led transformative work in unraveling the mechanisms of immune evasion in brain tumors, particularly glioblastoma. Her contributions have significantly advanced the understanding of tumor-mediated immunosuppression and informed the development of novel therapeutic strategies aimed at enhancing antitumor immunity.

As a Key Opinion Leader at Immunogenik, Dr. Heimberger brings unmatched insight and strategic guidance to the company’s clinical development programs and immunotherapy platforms. Her deep expertise helps drive forward Immunogenik’s mission to develop next-generation treatments for patients with aggressive and treatment-resistant solid tumors. Her involvement reinforces the company’s commitment to scientific excellence and clinical impact.